A New View on Biological Quality Control?

Scroll Down

Quality control is an integral and critical part of biologics development and manufacturing, encompassing both contamination control to data integrity. However, the quality of biologics can be impacted by minor variations in manufacturing processes, a problem seen often during the COVID-19 pandemic.

This article explores the changes made by biopharmaceutical companies and CDMOs to adapt to the “new normal”, drawing from the experiences of quality control experts including Natasha Rivas, Vice President of Quality and Regulatory, at Genezen.

Read the full article here: A New View on Quality Control?

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more